|
End-of-day quote
Korea S.E.
23/10/2026
|
5-day change | 1st Jan Change | ||
| 9,700.00 KRW | -3.39% |
|
+5.09% | +42.23% |
| 09/12 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/25/12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 26/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 27/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 29/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 30/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.39% | +5.09% | +33.24% | - | 17Cr | ||
| -1.07% | +1.20% | +14.09% | +35.52% | 12TCr | ||
| +0.37% | +2.22% | +4.92% | +103.82% | 10TCr | ||
| +0.64% | +2.67% | +109.83% | +890.32% | 5.82TCr | ||
| +1.75% | +2.27% | -5.92% | +83.08% | 2.91TCr | ||
| -0.57% | +2.93% | +32.78% | +95.74% | 2.66TCr | ||
| -0.30% | +3.46% | +17.70% | +65.59% | 2.67TCr | ||
| -0.81% | +0.45% | +27.60% | +378.95% | 2.16TCr | ||
| +1.48% | -4.05% | -22.32% | -8.19% | 1.96TCr | ||
| -0.68% | +2.72% | +3.48% | +85.69% | 1.89TCr | ||
| Average | -0.26% | +1.19% | +21.54% | +192.28% | 4.22TCr | |
| Weighted average by Cap. | -0.06% | +1.65% | +23.66% | +196.76% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















